JNJ-64264681 clinical trials
Also written JNJ-64264681.
How each study uses JNJ-64264681 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JNJ-64264681 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JNJ-64264681
- 4
Studies by the year they started
4 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Safimaltib (2) · Rezetamig (1) · Ibrutinib (1) · DHODH Inhibitor JNJ-74856665 (1) · Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902 (1) · JNJ-64619178 (1) · Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 (1) · JNJ-87801493 (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses JNJ-64264681 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationPhase 1Janssen Research & Development, LLCNCT06788509Written as JNJ-64264681
- A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedPhase 1Janssen Research & Development, LLCNCT04657224Written as JNJ-64264681
- A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedPhase 1Janssen Research & Development, LLCNCT04210219Written as JNJ-64264681
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03607513Written as JNJ-64264681
Codes
What other systems call JNJ-64264681 · ClinicalTrials.gg INT002041
- MeSH (NLM) C000729293JNJ-64264681One source ClinicalTrials.gov
- UNII (FDA) Y8U0XA0OJEJNJ-64264681One source FDA
- NCI Thesaurus C179289BTK Inhibitor JNJ-64264681One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729293 | JNJ-64264681 | One source ClinicalTrials.gov |
| UNII (FDA) | Y8U0XA0OJE | JNJ-64264681 | One source FDA |
| NCI Thesaurus | C179289 | BTK Inhibitor JNJ-64264681 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.